Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction

• Status: Completed
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to determine whether pharmacological treatment with N-acetylcysteine improves central and peripheral cardiorespiratory control and physical capacity in COPD patients with mild-to-moderate airflow obstruction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Queen's University
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• stable COPD with mild-to-moderate airflow obstruction as indicated by the low ratio between forced expiratory volume in one second and forced vital capacity (FEV1/FVC<0.7) together with post-bronchodilator FEV1≥60% predicted under optimized clinical treatment as judged by the accompanying physician

Exclusion Criteria:

• unable to perform all experimental procedures and/or provide informed consent;

• hospital admission in the previous 6 weeks;

• exercise training program in the previous 6 months;

• any condition that could interfere with the ability to exercise;

• diagnosed psychiatric or cognitive disorders;

• type I insulin-dependent diabetes mellitus;

• excessively over-weight (BMI>35kg/m²);

• other diagnosed cardiorespiratory disorders (e.g., chronic heart failure, peripheral artery disease).